Passage of cytokines across the blood-brain barrier

被引:590
|
作者
Banks, WA
Kastin, AJ
Broadwell, RD
机构
[1] TULANE UNIV, SCH MED, NEW ORLEANS, LA 70112 USA
[2] US PHS, OFF RES INTEGR, ROCKVILLE, MD USA
关键词
interleukin-1; alpha; beta; interleukin-1 receptor antagonist; interleukin-2; interleukin-6; tumor necrosis factor-alpha; transport; brain; behavior; autoradiography; efflux;
D O I
10.1159/000097202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One mechanism by which blood-borne cytokines might affect the function of the central nervous system (CNS) is by crossing the blood-brain barrier (BBB) for direct interaction with CNS tissue. Saturable transport systems from blood to the CNS have been described for interleukin (IL)-1 alpha, IL-1 beta, IL-1 receptor antagonist (IL-1ra), IL-6, and tumor necrosis factor-alpha (TNF-alpha). Blood-borne cytokines have been shown to cross the BBB to enter cerebrospinal fluid and interstitial fluid spaces of the brain and spinal cord. IL-2 does not cross the BBB by a saturable transport system. The blood-to-brain uptakes of IL-1 alpha, IL-beta, and IL-1ra are interrelated for most brain sites, but the posterior division of the septum shows selective uptake of blood-borne IL-1 alpha. The saturable transport systems for IL-6 and TNF-alpha are distinguishable from each other and from the IL-1 systems. The amount of blood-borne cytokines entering the brain is modest but comparable to that of other water-soluble compounds, such as morphine, known to cross the BBB in sufficient amounts to affect brain function. CNS to blood efflux of cytokines has also been shown to occur, but the mechanism of passage is unclear. Taken together, the evidence shows that passage of cytokines across the BBB occurs, providing a route by which blood-borne cytokines could potentially affect brain function.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 50 条
  • [41] Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood-Brain Barrier Both in Vitro and in Vivo
    Aparicio-Blanco, Juan
    Romero, Ignacio A.
    Male, David K.
    Slowing, Karla
    Garcia-Garcia, Luis
    Torres-Suarez, Ana I.
    MOLECULAR PHARMACEUTICS, 2019, 16 (05) : 1999 - 2010
  • [42] Blood Serum Cytokines Induce Changes in Blood-Brain Barrier Permeability and Gene Expression in an <it>In Vitro</it> Blood-Brain Barrier Model
    Ho, Dao
    Kelly, Gillian
    FASEB JOURNAL, 2020, 34
  • [43] PASSAGE OF NEUROPEPTIDES ACROSS THE BLOOD-BRAIN-BARRIER
    BANKS, WA
    KASTIN, AJ
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1988, 10 (01) : 39 - 40
  • [44] PASSAGE OF IMMUNOMODULATORS ACROSS THE BLOOD-BRAIN-BARRIER
    STITT, JT
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 1990, 63 (02): : 121 - 131
  • [45] The passage of neutral amino acids across the blood-brain barrier of individual brain structures in normal and encephalopathic rats
    Hawkins, Richard A.
    Mans, Anke M.
    Biebuyck, Julien F.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1980, 8 : 609 - 610
  • [46] Stereoselective passage of mefloquine through the blood-brain barrier in the rat
    Baudry, S
    Pham, YT
    Baune, B
    Vidrequin, S
    Crevoisier, C
    Gimenez, F
    Farinotti, R
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (11) : 1086 - 1090
  • [47] Blood-brain barrier - Size matters at the blood-brain barrier
    Green, E
    NATURE REVIEWS NEUROSCIENCE, 2003, 4 (07) : 525 - 525
  • [48] RELATIONSHIP BETWEEN PASSAGE OF LOCAL ANAESTHETICS ACROSS BLOOD-BRAIN BARRIER AND THEIR EFFECTS ON CENTRAL NERVOUS SYSTEM
    USUBIAGA, JE
    MOYA, F
    WIKINSKI, JA
    WIKINSKI, R
    USUBIAGA, LE
    BRITISH JOURNAL OF ANAESTHESIA, 1967, 39 (12) : 943 - &
  • [49] Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease
    Banks, WA
    Terrell, B
    Farr, SA
    Robinson, SA
    Nonaka, N
    Morley, JE
    PEPTIDES, 2002, 23 (12) : 2223 - 2226
  • [50] Efflux transport of tolbutamide across the blood-brain barrier
    Takanaga, H
    Murakami, H
    Koyabu, N
    Matsuo, H
    Naito, M
    Tsuruo, T
    Sawada, Y
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (09) : 1027 - 1033